Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

For tough AML, half respond to selinexor plus chemotherapy

Publish date:: June 25, 2019

Key clinical point: Patients with relapsed or refractory acute myeloid leukemia may be more likely to respond when selinexor is added to standard chemotherapy.

Major finding: The overall response rate was 50% for patients receiving cytarabine, idarubicin, and selinexor.

Study details: A phase 2 trial involving 44 patients with relapsed or refractory acute myeloid leukemia.

Disclosures: The study was funded by Karyopharm Therapeutics. Dr. Fielder reported financial disclosures related to Amgen, Pfizer, Jazz Pharmaceuticals, and other companies.

Citation:

Fiedler W et al. EHA Congress, Abstract S880.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in AML

Beat AML: Precision medicine strategy feasible, superior to SOC for AML,

Survey quantifies COVID-19’s impact on oncology,

Combo drug improves survival in older patients with high-risk/secondary AML,

Venetoclax plus LDAC tops LDAC alone in AML,

Azacitidine plus enasidenib improves response, but not survival, in mIDH2 AML,